Medicare will notify you after the request is reviewed
A 2025 UCSF open-label pilot in Parkinsons disease, the first test of a psychedelic in a neurodegenerative disease, found that two sessions improved mood, cognition, and motor symptoms for weeks to months, with a larger randomized trial now under way
It competitively binds p53, displacing endogenous FOXO4 in senescent cells (Baar et al., 2017) 24-72 hours: Freed p53 translocates to mitochondria in senescent cells, triggering the intrinsic apoptotic cascade
Common side effects Nausea Diarrhea or constipation Vomiting Abdominal pain Fatigue Serious risks Pancreatitis (inflammation of the pancreas) Gallbladder problems Low blood sugar, especially with other diabetes medicines Kidney problems related to dehydration Serious allergic reactions Do not use if you have Personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Known serious allergy to semaglutide Pregnancy or breastfeeding How it compares Frequently asked questions What is compounded semaglutide
Robust direct comparisons of clinical outcomes are lacking
(2011) 300:E103846